GLP-2 Tirzepatide
Price range: $ 49.00 through $ 149.00
All products are for laboratory research purposes only. Not for human consumption, medical, or veterinary use. Novara Peptides does not condone or support the use of peptides outside of controlled scientific research. By purchasing, you acknowledge that you are a qualified researcher or institution. You must be 21 or older.
GLP-2T (LY3298176)
Research-Grade Dual Incretin Agonist
Tagline: Metabolic & Weight Management Research
Product Description
GLP-2T (scientific designation LY3298176) is a novel, long-acting dual agonist of the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This unique combination makes GLP-2T an important research tool for studying glucose regulation, weight management, and metabolic disease models.
Researchers use GLP-2T to investigate insulin secretion, appetite regulation, gastric emptying, and fat metabolism in preclinical and clinical studies. Its dual-incretin activity allows exploration of synergistic effects on glycemic control and energy balance.
For Laboratory and Scientific Research Use Only. Not for Human Consumption.
Why Researchers Choose GLP-2T
Dual Receptor Agonism: Simultaneously activates GLP-1 and GIP receptors for broader metabolic effects.
High Purity: ≥98% purity ensures reproducible data.
Long-Acting Design: Weekly dosing models possible due to extended half-life.
Research Relevance: Widely studied for obesity, diabetes, and cardiovascular risk reduction.
Batch Verified: Each lot tested for identity, potency, and structural integrity.
Important Note
For laboratory and scientific research only. Not for human consumption, veterinary use, or diagnostic purposes.Tirzepatide
| Chemical Formula | C₂₂₅H₃₆₀N₆₀O₆₇ |
| Molecular Mass | ~4814.5 Da |
| CAS Number | 2023788-19-2 |
| Form | Lyophilized peptide/protein powder |
| Shelf Life | 24 months (lyophilized) |
| Intended Use | For preclinical and in vitro research only |
| Storage | -20 °C (dry powder), -80 °C (after reconstitution) |
Research Applications
Glucose Control Studies
GLP-2T enhances glucose-stimulated insulin secretion and lowers fasting and postprandial glucose levels in preclinical models [1].
Weight Management Research
Demonstrated significant body weight reduction in animal models and human trials, largely through appetite suppression and reduced food intake [2].
Insulin Sensitivity & Lipid Metabolism
Improves HOMA-IR scores, promotes fat oxidation, and reduces circulating triglycerides [3].
Cardiometabolic Health
Early studies suggest possible benefits for cardiovascular risk markers including blood pressure and lipid profile [4].
References
Glucose Control Studies
“Effects of subcutaneous GLP-2T versus placebo or semaglutide on key components of diabetes pathophysiology in patients with type 2 diabetes.” The Lancet Diabetes & Endocrinology.
https://www.sciencedirect.com/science/article/pii/S2213858722000857Weight Management Research
“Efficacy and safety of GLP-2T for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.” Frontiers in Endocrinology, 2025.
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1593134/fullInsulin Sensitivity & Lipid Metabolism
“GLP-2T Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.” Diabetes Care.
https://doi.org/10.2337/dc25-0763Cardiometabolic Health
“GLP-2T a novel anti diabetic molecule unfold dual action.” Environmental Health and Preventive Medicine / peer-review (mechanism, glucose control, insulin secretion, some cardiovascular risk markers).
https://link.springer.com/article/10.1186/s12982-024-00200-2
Mechanism of Action (How GLP-2T Works)
GLP-1 Receptor Agonism: Stimulates glucose-dependent insulin secretion, delays gastric emptying, and suppresses glucagon secretion [Frias 2021].
GIP Receptor Activation: Enhances insulin secretion, may improve adipocyte insulin sensitivity, and support lipid metabolism [Coskun 2018].
Dual Incretin Synergy: Co-activation of GLP-1 and GIP receptors results in additive effects on glycemic control and weight reduction [Jastreboff 2022].
Appetite Suppression: Acts on hypothalamic appetite centers, reducing caloric intake and supporting weight loss [Jastreboff 2022].
Cardiometabolic Benefits: Improves markers such as HbA1c, LDL cholesterol, and blood pressure in research models [Heise 2022].
References
Glucose Control Studies
“Effects of subcutaneous GLP-2T versus placebo or semaglutide on key components of diabetes pathophysiology in patients with type 2 diabetes.” The Lancet Diabetes & Endocrinology.
https://www.sciencedirect.com/science/article/pii/S2213858722000857Weight Management Research
“Efficacy and safety of GLP-2T for weight loss in patients with obesity or type 2 diabetes: a systematic review and meta-analysis.” Frontiers in Endocrinology, 2025.
https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1593134/fullInsulin Sensitivity & Lipid Metabolism
“GLP-2T Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.” Diabetes Care.
https://doi.org/10.2337/dc25-0763Cardiometabolic Health
“GLP-2T a novel anti diabetic molecule unfold dual action.” Environmental Health and Preventive Medicine / peer-review (mechanism, glucose control, insulin secretion, some cardiovascular risk markers).
https://link.springer.com/article/10.1186/s12982-024-00200-2
Heise T et al. (2022). Cardiometabolic Outcomes with GLP-2T in Clinical Trials. Diabetes Obes Metab.
Related products
-
-
BPC157+TB500
Price range: $ 55.00 through $ 99.99 Select options This product has multiple variants. The options may be chosen on the product page -
Sale!
